Want to see ERAS full AI Analyst Report?
ERAS Stock Chart & Stats
$19.01
-$0.05(-2.00%)
At close: 4:00 PM EST
$19.01
-$0.05(-2.00%)
Day’s Range― - ―
52-Week Range$1.33 - $24.28
Previous CloseN/A
Volume148.24K
Average Volume (3M)5.58M
Market Cap
$6.77B
Enterprise Value$4.73K
Total Cash (Recent Filing)$243.79M
Total Debt (Recent Filing)$45.95M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Aug 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding347,127,400
10 Day Avg. Volume5,737,873
30 Day Avg. Volume5,582,593
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-11.03
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$22.40Price Target Upside17.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Compelling Early Clinical EfficacyPhase 1 readouts show high response rates and manageable safety for ERAS-0015 across KRAS-mutant tumors, supporting progression to registration‑enabling and Phase 3 trials. Durable clinical validation of a lead asset materially strengthens the company’s long-term commercial potential and partner appeal.
Substantial Equity Financing To Fund R&DA large primary equity raise meaningfully expands near-term funding capacity, reducing immediate runway risk and enabling acceleration of multiple clinical programs. This structural financing cadence supports program advancement without relying solely on partnerships or debt, preserving operational flexibility.
Manageable Leverage And Sizable Equity BaseBalance sheet metrics show relatively low leverage and a meaningful equity cushion versus peers in development-stage biotech. That structural capital base provides a firmer foundation to fund clinical milestones and absorb dilution, although sustained losses remain a countervailing risk over time.
Bears Say
No Revenue; Persistent Large LossesThe company lacks commercial revenue and records sizable, recurring operating and net losses. Over the medium term this undermines self-funding capacity, increases reliance on external capital, and creates risk that clinical setbacks will pressure resources and strategic options.
Accelerating Negative Cash Flow And High BurnConsistently negative operating and free cash flow with an accelerating burn rate is a structural vulnerability. Even with equity raises, sustained high cash consumption increases dilution risk and could force financing at unfavorable terms if clinical timelines slip or costs rise.
Material Legal/IP Risk Around Lead AssetA formal allegation of patent infringement and misappropriation against ERAS-0015 poses significant long-term risk: potential injunctions, costly litigation, or licensing needs could delay development, increase expenses, and reduce the commercial upside of the company’s core program.
Erasca News
ERAS FAQ
What was Erasca, Inc.’s price range in the past 12 months?
Erasca, Inc. lowest stock price was $1.33 and its highest was $24.28 in the past 12 months.
What is Erasca, Inc.’s market cap?
Erasca, Inc.’s market cap is $6.77B.
When is Erasca, Inc.’s upcoming earnings report date?
Erasca, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 13 days.
How were Erasca, Inc.’s earnings last quarter?
Erasca, Inc. released its earnings results on May 11, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.104 by -$0.496.
Is Erasca, Inc. overvalued?
According to Wall Street analysts Erasca, Inc.’s price is currently Undervalued.
Does Erasca, Inc. pay dividends?
Erasca, Inc. does not currently pay dividends.
What is Erasca, Inc.’s EPS estimate?
Erasca, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Erasca, Inc. have?
Erasca, Inc. has 347,127,400 shares outstanding.
What happened to Erasca, Inc.’s price movement after its last earnings report?
Erasca, Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.104. Following the earnings report the stock price went down -0.575%.
Which hedge fund is a major shareholder of Erasca, Inc.?
Currently, no hedge funds are holding shares in ERAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Erasca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.40 (17.83% Upside)
$22.40 (17.83% Upside)
Blogger Sentiment
Bullish
ERAS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 965.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.9%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1061.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.12%
Trailing 12-Months
Company Description
Erasca, Inc.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
ERAS Stock 12 Month Forecast
Average Price Target
$22.40
▲(17.83% Upside)
Technical Analysis
Arcturus Therapeutics
―
Arvinas Holding Company
―
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
9.72% Insiders
11.43% Mutual Funds
0.33% Other Institutional Investors
67.57% Public Companies and Individual Investors